No Data
ADC Therapeutics Price Target Maintained With a $10.00/Share by Guggenheim
ADC Therapeutics Stock Plunges 36% Amid Zynlonta Data Release
H.C. Wainwright Maintains ADC Therapeutics(ADCT.US) With Buy Rating, Maintains Target Price $8
Promising Efficacy in LOTIS-7 Trial Boosts Buy Rating for ADC Therapeutics
Express News | ADC Therapeutics SA - No Dose-Limiting Toxicities or High-Grade Crs/Icans Observed
ADC Therapeutics Announces Positive Initial Data From LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination With Bispecific Antibody in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
102539778 : nah this was just criming
hotboyz : it's going up now